Cost-Effectiveness Analysis of Certolizumab, Etanercept, Golimumab And Tofacitinib for The Treatment of Moderately To Severely Active Rheumatoid Arthritis
May 1, 2015, 00:00 AM
10.1016/j.jval.2015.03.937
https://www.valueinhealthjournal.com/article/S1098-3015(15)00994-8/fulltext
Section Title :
Muscular-Skeletal Disorders
Section Order :
389
First Page :
A162
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)00994-8&doi=10.1016/j.jval.2015.03.937